Elaine Shum, MD
Following frontline TKI approvals, researchers are still trying to determine the role of older-generation TKIs in the treatment of patients with oncogene-driven non–small cell lung cancer (NSCLC), as well as ways to overcome acquired resistance to these agents, said Elaine Shum, MD.
State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Shum, a medical oncologist at NYU Langone’s Perlmutter Cancer Center, discussed the rapidly evolving treatment options for patients with oncogene-driven NSCLC.
OncLive: What are the updates in frontline options for patients with oncogene-driven NSCLC?
: It has been a very exciting past couple of years in terms of new FDA approvals for drugs in the frontline setting. In my presentation [at the State of the Science SummitTM], I focused on ALK- and EGFR-[targeted therapies], and I also touched on some of the rarer oncogenic drivers.
... to read the full story